Vertex Pharma (VRTX): Kalydeco Miss Is Not A Game Changer - Jefferies
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) after the company announced that '661/Kalydeco missed on its interim efficacy analysis in het/min CF patients.
Success would have created an opportunity to reach this large subpopulation with the dual combo and reaffirmed '661's activity (given its importance as a backbone for the triple). However, the analyst believes expectations were low, and the event does not change his overall positive CF franchise view.
No change to the price target of $107.
Shares of Vertex closed at $102.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades PayPal (PYPL) to Buy Following 'Solid' Q3 Results
- Imperial Capital Raises Price Target on American Airlines (AAL) Following 3Q EPS Beat
- Jefferies Cuts Price Target on Reliance Steel (RS) Following 3Q EPS Miss and Guidance
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, FDA
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!